Loss of a cell's ability to terminally differentiate because of mutations is a selected genetic event in tumorigenesis. Genomic analyses of low-grade glioma have reported recurrent mutations of far upstream element-binding protein 1 (FUBP1). Here, we show that FUBP1 expression is dynamically regulated during neurogenesis and that its downregulation in neural progenitors impairs terminal differentiation and promotes tumorigenesis collaboratively with expression of IDH1
INTRODUCTION
Neural stem cells in the mammalian brain both self-renew and differentiate to produce neurons in a controlled manner (Kriegstein and Alvarez-Buylla, 2009 ). These cells follow the developmental hierarchy and differentiate into replication-arrested mature cells (Gage, 2000) . Aberrant regulation of cellular differentiation may underlie various human developmental disorders, pathological conditions, and diseases including cancer. Glioma cells often exhibit anomalous developmental programs that disable terminal differentiation and sustain self-renewal (Jackson et al., 2006; Sanai et al., 2005) . Restoration of differentiation capacities of glioma cells reduces tumorigenic potential, supporting the idea that impaired terminal differentiation contributes to glioma pathogenesis (Zheng et al., 2008 (Zheng et al., , 2010 .
Far upstream element-binding protein 1 (FUBP1) is a single-strand DNA-and RNA-binding protein. It regulates transcription, mRNA stability and translation, and splicing (Zhang and Chen, 2013) . It is frequently overexpressed in several types of cancer, including hepatocellular carcinoma, non-small cell lung carcinoma, and gastric cancer; thus, it is considered a proto-oncogene (Baumgarten et al., 2014; Li et al., 2013; Malz et al., 2009; Rabenhorst et al., 2009; Singer et al., 2009; . Paradoxically, recent genomic studies on 1p19q co-deleted low-grade gliomas uncovered a frequent loss of FUBP1 functions in oligodendrogliomas (ODGs) by loss of heterozygosity of 1p and inactivating mutations, suggesting the potential of FUBP1 as a tumor-suppressor gene (Bettegowda et al., 2011; Sahm et al., 2012; Yip et al., 2012) .
Existing genetic studies point to the role of FUBP1 in maintaining hematopoietic stem cells and supporting proliferation of neoplastic cells (Rabenhorst et al., 2009 (Rabenhorst et al., , 2015 . A Fubp1 germline knockout (Fubp1 À/À ) mouse was shown to be embryonic lethal starting at embryonic day 10.5. Phenotypically, these animals displayed a small body size associated with hypoplasia of multiple tissues with the exception of cerebral hyperplasia, suggesting a context-specific function of Fubp1 (Zhou et al., 2016) . Fubp1 À/À embryos presented notable overall brain parenchymal hypercellularity without the normal lobation of the cerebellum and obvious organization of the diencephalic cortical layers (Zhou et al., 2016) . LSD1 (also known as KDM1A) is necessary for selfrenewal of neural progenitor cells (NPCs) by repressing TLX target genes including CDKN1A and PTEN (Sun et al., 2010) . It represses and activates transcription by mediating histone H3K4me1/2 and H3K9me1/2 or H4K20me3 demethylation, respectively (Laurent et al., 2015; Wang et al., 2007 Wang et al., , 2015 . Its expression is post-translationally downregulated by ubiquitin-mediated degradation during neurogenesis (Han et al., 2014) . Sustaining its transcription during neurogenic differentiation is necessary, as its neuron-specific isoform LSD1+8a is essential for terminal differentiation and maturation of neurons. Silencing of the neurospecific splice variant LSD1+8a delays neurite maturation in cortical neuronal cultures (Zibetti et al., 2010) . Similarly, LSD1+8a promotes terminal neuronal differentiation by demethylating H3K9me1/2, which then derepresses neuronal gene expression (Laurent et al., 2015) . In addition, it regulates neuronal activityregulated transcription that is necessary for long-term memory formation by demethylating H4K20 .
FUBP1 is frequently overexpressed in many human cancers and strongly correlated with disease progression (Baumgarten et al., 2014; Li et al., 2013; Malz et al., 2009; Rabenhorst et al., 2009; Singer et al., 2009; . However, how it serves uniquely as a tumor suppressor in the brain is so far left unanswered. In this study, we hypothesized that FUBP1 plays an indispensable role in promoting terminal differentiation of neurons, and that lack of FUBP1 interferes with early-born neuronal cells exiting the cell cycle and predisposes these cells for transformation. Our study provides insights into the mechanism of how FUBP1 and isocitrate dehydrogenase (IDH) mutations together may converge on epigenetic aberrations and impair differentiation.
RESULTS

Expression of FUBP1 Is Regulated during Neurogenesis
FUBP1 is broadly expressed throughout the adult brain, primarily observed in the nucleus of neurons ( Figure S1A ). The glia-rich corpus callosum lacks FUBP1-positive cells, indicating neuronally enriched expression of FUBP1 in the adult brain. Consistently, double immunostaining of FUBP1 with a neuronal marker NeuN was strongly positive. In contrast, with an oligodendrocyte marker, Olig2 + , or an astrocyte marker, glial fibrillary acidic protein (GFAP) + , cells showed a very low expression of FUBP1 ( Figure S1B ). We examined the expression of FUBP1 in neurogenic areas of the adult brain in order to understand its role during brain development. It is highly expressed in NESTIN-positive progenitors and NeuN-positive mature neurons ( Figures  1A and 1B) . Notably, doublecortin (DCX)-positive neuroblasts in the subgranular zone showed low to no signals while migrating ones in the granular cell layer increased its expression to intermediate to strong levels ( Figures 1C  and 1D ). These results suggest that the expression of FUBP1 is dynamically regulated during neurogenesis and may control key steps in committing to neuronal lineage and maturing into terminally differentiated neurons ( Figure 1E ). Next, we tested whether this expression pattern is recapitulated in our neural progenitor cell cultures. Homozygous deletion or silencing of Ink/Arf locus is one of the most frequent genetic lesions of gliomas (Cancer Genome Atlas Research Network et al., 2015) . We therefore used immortalized Ink/Arf À/À NPCs that maintain their multi-lineage differentiation capability (Bruggeman et al., 2005 Figure S2A ). NPC ND1 cells effectively differentiate to DCX-expressing neuroblasts ($30%), within 2 days, in the presence of doxycycline ( Figure S2B ). In this system, almost all cells become quiescent within 5-7 days, as evidenced by a lack of 5-bromo-2 0 -deoxyuridine (BrdU)-positive cells following extended exposure ( Figure S2C ). During the early differentiation, the expression of FUBP1 declined followed by a progressive increase, while the neuronal marker NeuN continued to increase at mRNA and protein levels ( Figures 1F and 1G ). These results corroborate our findings that FUBP1 expression is regulated during neuronal differentiation.
Loss of FUBP1 Inhibits Terminal Neuronal Differentiation
Given that FUBP1 is precisely controlled in multiple steps during neuronal differentiation, we queried the role of FUBP1 in terminal neuronal differentiation and maturation. We knocked down the expression of FUBP1 in the NPC ND1 line (NPC ND1 FUBP1 KD ). Two independent short hairpins for FUBP1 effectively decreased its expression (Figure S2D) . Because both hairpins elicited indistinguishable biological outcomes ( Figure S3A ), we present detailed results from cultures generated from hairpin 1 for the current study. Clearly, the frequency of NeuN-or MAP2a/b-positive cells was significantly decreased in NPC ND1 FUBP1 KD (F) qRT-PCR analysis of neuronal markers and FUBP1 expression by NPCs at indicated times after the onset of differentiation (mean ± SEM from 3 independent cultures).
(G) Representative western blot analysis of proliferating and differentiating NPC ND1 (+doxycycline) cells. Band intensities are indicated below each blot. SGZ, subgranular zone; GCL, granular cell layer. See also Figure S1 . (Figures 2A and 2B ). To determine whether impaired terminal differentiation resulted from a failure to exit the cell cycle, we performed a DNA synthesis-based cell proliferation assay. The number of BrdUpositive NPC ND1 cells declined within 48 hr of differentiation initiation and became undetectable after prolonged (5-7 days) differentiation ( Figure 2C) . KD (E) were determined by qPCR (mean ± SEM from 3 independent cultures). Statistical significance was determined by one-way ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figures S2 and S3.
CDK4/6 inhibitor, suppressed BrdU incorporation but failed to restore neuronal differentiation ( Figure S3A and data not shown). These results together suggest that sustained proliferation is due to the impaired terminal differentiation rather than the direct role of FUBP1 in cell-cycle regulation.
FUBP1 Promotes the Expression of LSD1+8a during Neuronal Differentiation
Recent studies suggested a context-dependent splicingregulatory function of FUBP1 (Jacob et al., 2014; Li et al., 2013; Miro et al., 2015) . In agreement, many interacting proteins identified by mass spectrometry and confirmatory co-immunoprecipitation analysis belong to components of spliceosomes (e.g., PTBP2, NOVA1 and NOVA2, and SRRM4) (Table S1 and Figure S4 ), raising the possibility that FUBP1 could have a functional role in splicing control during neuronal differentiation. In particular, the interaction between FUBP1 and SRRM4 appears indirect and RNA dependent as it is abolished by RNase A treatment ( Figure S4) . Notably, our analysis of RNA-seq experiments for global alternative splicing (AS) events occurring in differentiating FUBP1 KD NPC showed increased exon skipping consistent with its reported function in exon inclusions (Jacob et al., 2014; Miro et al., 2015) ( Figure S5 ). In addition, we calculated Z score of differential exon usage focusing on transcripts with little to no expression changes between NT KD and FUBP1 KD cells. From the analysis, 838 differentially used exons with Z score of larger than 2 corresponding to 689 genes were identified, further supporting the role of FUBP1 in AS control (Table S2) . Among those neuron-specific splicing factors, we noted that the expression of SRRM4 is gradually increased in differentiating NPC ND1 cells ( Figure 2D ), consistent with its role in neuronal differentiation and maturation (Quesnel-Vallières et al., 2015) . However, it failed to increase beginning from differentiation day 3 in NPC ND1 FUBP1 KD cells ( Figure 2E ). These results suggest that loss of FUBP1 affects SRRM4 expression, likely due to impaired neuronal differentiation. Previously, several lines of evidence have suggested that LSD1 has a critical role in NPC differentiation and neuronal maturation. The LSD1 gene, which is highly conserved among vertebrates, consists of 19 exons. However, due to the existence of two additional exons (exon 2a and exon 8a) that can be included in mature LSD1 mRNA, four different LSD1 transcripts can be generated. Among these isoforms, LSD1+8a, which contains miniexon 8a, is exclusively expressed in the nervous system (Zibetti et al., 2010) . In addition, the expression of the LSD1+8a isoforms is upregulated during neuronal differentiation and throughout cortical development (Laurent et al., 2015; Zibetti et al., 2010) . Downregulation of LSD1+8a strongly inhibited neurite outgrowth and abrogated the establishment of the neurite network. A previous study reported that neuron-specific splicing factors such as SRRM4 and NOVA1 are necessary for LSD1+8a expression (Rusconi et al., 2015) .
Because (1) loss of FUBP1, SRRM4, or LSD1+8a impaired neuronal differentiation (Laurent et al., 2015; Raj et al., 2011) (Figures 2A and 2B ), (2) FUBP1 and SRRM4 are functionally associated ( Figure 2E ), and (3) AS of LSD1 is critical during neuronal maturation, we hypothesized that FUBP1 along with SRRM4 may be required for the splicing of LSD1 to include mini-exon 8a. First, we analyzed the expression of LSD1+8a and LSD1À8a by using specific primers that detect each isoform ( Figure 3A ). Neuronal differentiation by NeuroD1 induction time-dependently increased the mRNA expression level of LSD1+8a in NPC ND1 while the levels of total LSD1 or LSD1À8a were only modestly increased ( Figure 3B ). It is noteworthy that LSD1À8a is much more abundant than LSD1+8a and accounts for the majority of LSD1 transcripts. Next, we tested whether loss of FUBP1 can influence the production of alternatively spliced isoforms of LSD1. Figure 3E ). In contrast, it failed to increase LSD1+8a expression and NeuN expression on day 3 of differentiation in NPC ND1 FUBP1 KD cells (Figure 3F) . These results together suggest that SRRM4 expression at early stages and FUBP1 levels in later stages of differentiation play a role as rate-limiting factors of LSD1+8a expression. To test whether FUBP1 or SRRM4 physically associate with LSD1+8a pre-mRNA and regulate the splicing of mini-exon 8a during neuronal differentiation, we performed an RNA-immunoprecipitation (RNA-IP) experiment with differentiating NPC ND1 . We conducted the experiment 2.5 days after the onset of differentiation, when the expression of FUBP1, SRRM4, and LSD1+8a increases as the majority of NPC ND1 cells transit through late DCX stages ( Figures 2D, 3B , 4A, and S2B). We searched for the TG-rich FUBP1-binding motif (Miro et al., 2015) in intron 8 and 8a of LSD1, and designed multiple pairs of primers that span the putative FUBP1-binding sites (Figures 4B and S6) . We identified two strong binding sites (R1 and R5) among five candidates ( Figures 4C, 4D , and S4). Similarly, SRRM4 showed strong binding near the 3 0 end of intron 8, where the polypyrimidine tract preceding the putative UGC motif is present ( Figures 4D and S6 ). The set of primers designed for a gene desert region failed to amplify RNA pulled down by immunoglobulin G (IgG), FUBP1, or SRRM4 antibodies, demonstrating the specificity of RNA-IP ( Figures 4C and 4D ). Primers amplifying the exonic region of GAPDH, which is not subject to FUBP1-or SRRM4-mediated splicing, failed to be enriched by the pull-down ( Figure 4D ).
To define the functional interaction between FUBP1 and SRRM4 in exon 8a inclusion, we performed a mini-gene reporter analysis (Cooper, 2005) (Figure 4E ). Enforcing the expression of either FUBP1 or SRRM4 synergistically enhanced exon 8a inclusion ( Figure 4F ). Consistent with the RNA-IP result, mutations of either SRRM4 binding site or R5 ( Figure 4E ) abolished exon 8a inclusion (Figure 4G) . Together, our results suggest that FUBP1 and SRRM4 bind to different regions within the introns 8 and 8a of LSD1 pre-mRNA and promote the inclusion of mini-exon 8a by AS in differentiating neurons. The LSD1+8a isoform may promote neuronal gene expression and generation of mature neurons as previously demonstrated (Laurent et al., 2015; Wang et al., 2015; Zibetti et al., 2010 ) ( Figure 4H ). A set of PCR primers with their location depicted as green arrows in (A) were used. Band intensity was plotted (mean ± SEM from 3 independent cultures). Statistical significance was determined by unpaired t tests. Relative mRNA levels of indicated genes were determined from NPC ND1 NT KD versus NPC ND1 FUBP1 KD with human SRRM4 expression under proliferation (E) or on day 3 of differentiation (F) (mean ± SEM from 3 independent cultures). *p < 0.05; **p < 0.01; ***p < 0.001. Statistical significance was determined by one-way ANOVA. See also Figure S4 . 5D ). These observations suggest that expression of LSD1+8a is necessary for timely coordination of differentiation and cell-cycle exit to complete neurogenesis. Collectively, our results support the hypothesis that FUBP1 is a rate-limiting factor for the expression of necessary levels of LSD1+8a isoform and therefore essential for terminal neuronal differentiation. Next, we queried whether LSD1+8a expression depends on FUBP1 under pathological conditions. Frequent loss of heterozygosity (LOH) of FUBP1 in 1p19q co-deleted ODG has been reported (Bettegowda et al., 2011; Cancer Genome Atlas Research Network et al., 2015) . We have identified 8 tumors with FUBP1 LOH out of 12 ODGs ( Figure 6A ). Notably, these tumors showed significantly reduced expression of LSD1+8a but not LSD1À8a, corroborating our mechanistic findings (p = 0.0238, Figure 6B ).
Loss of FUBP1 in the Background of IDH1
R132H -Expressing NPCs Promotes Tumorigenesis In Vivo FUBP1 mutations are associated with neomorphic IDH1 or 2 mutations (R132H or R172K, respectively) and inactivating mutations in capicua (CIC) on 19q13 (Bettegowda et al., 2011; Hartmann et al., 2010; Ichimura et al., 2009; Parsons et al., 2008; Reitman and Yan, 2010; Sahm et al., 2012; Yan et al., 2009; Yip et al., 2012) Figure 6G ). Taken together, we find that loss of FUBP1 critically contributes to the initiation of tumorigenesis by sustaining the proliferation of IP NPCs in vivo.
DISCUSSION
The importance and non-redundant role of FUBP1 in the development of the mammalian brain has been demonstrated (Zhou et al., 2016) . Nevertheless, the role of FUBP1 in lineage commitment and terminal differentiation of NPCs is uncharted. Our study demonstrated that FUBP1 expression is dynamically regulated during NPC differentiation and is indispensable for terminal neuronal maturation. Similarly, a recent study reported that loss of FUBP1 expression in embryonic stem cells delayed differentiation into the mesoderm germ layer, or diminished differentiation into the erythroid lineage, further corroborating its context-specific function in cell-fate regulation (Wesely et al., 2017) . Similar to several other neuronal differentiation splicing factors such as PTBP2 and RBFOX1, its loss critically contributes to gliomagenesis through trapping NPCs in a slowly proliferating progenitor-like state (F and G) Mini-gene reporter assay following the transient transfection of indicated reporters and exogenous SRRM4 and FUBP1 (mean ± SEM from 3 independent experiments). Statistical significance was determined by one-way ANOVA. **p < 0.01; ****p < 0.0001. (H) A schema for FUBP1 regulation of LSD1+8a expression and differentiation. See also Figures S4-S6 .
in the background of IDH1 R132H expression. Prior to our study, the majority of biological functions of FUBP1 was paradoxically attributed to promoting proliferation. In agreement with this assumption, most human cancers were shown to express high levels of FUBP1, which predict poor prognosis (Baumgarten et al., 2014; Li et al., 2013; Malz et al., 2009; Rabenhorst et al., 2009; Singer et al., 2009; . Our identification of LSD1+8a as a downstream effector of FUBP1 action in neuronal differentiation may explain the molecular mechanism of how FUBP1 and IDH1 mutations collaborate during gliomagenesis. LSD1+8a acts as demethylase of H3K9me2 that is required for derepression of gene expression for terminal neuronal differentiation (Laurent et al., 2015) . Previous studies showed that IDH1 R132H -expressing NPCs failed to differentiate to the astrocytic marker GFAP or neuronal marker MAP2-and Synapsin 1-positive cells (Lu et al., 2012; Rosiak et al., 2016) . Impaired lineage differentiation was in part explained by 2-hydroxyglutarate (2-HG) produced by IDH1 R132H , which inhibits histone demethylases including H3K9me2/3-demethylating KDM4C. This leads to the Figure 4H ). What tethers FUBP1 to the transcriptional regulator complex in proliferating cells as reported by others, and to spliceosomes responsible for the inclusion of exon 8a to the LSD1 transcript during terminal differentiation of neurons, remains to be further defined. Interestingly, our mass spectrometry analysis of FUBP1-interacting proteins identified SWI/SNF chromatin remodeling factors and histone subunits (Table S1 ). This is in agreement with the previously demonstrated role of FUBP1 as a transcriptional regulator. In particular, FUBP1 was shown to bind to the far upstream sequence element, only in proliferating cells, and upregulate c-Myc expression. It is plausible that specific epigenetic modifications or transcription machineries are required for FUBP1-mediated transcriptional regulation.
We also noted that mRNA levels and protein expression of FUBP1 are not always collinear. For example, FUBP1 protein levels are deeply reduced by a 20%-30% knockdown of its mRNA levels ( Figure S2D) . A previous study also reported such a discrepancy, suggesting possible regulation at post-translational levels (Wesely et al., 2017) . Indeed, FUBP1 was identified as an authentic PARKIN E3 ligase substrate (Ko et al., 2006) . How protein stability plays a role in FUBP1-dependent biological functions including neurogenic differentiation warrants further study.
Our mechanistic findings of FUBP1 action in glioma suppression warrant future investigations. Currently ODG is incurable despite the favorable prognosis. Our study may strengthen the rationale for novel mechanism-driven therapeutic strategies. Re-expression of key effector genes necessary for terminal differentiation may reduce undifferentiated progenitor state cells. One such approach would be normalization of aberrantly marked repressive H3K9me2/3 by inhibitors of H3K9 methyltransferases G9a or GLP. In a recent study, a dual G9a/GLP inhibitor UNC0642 was effective in restoring ATM expression and its function in IDH1-mutant hematopoietic cells where H3K9 methylation at the ATM promoter was elevated and transcriptionally repressive (Inoue et al., 2016) . Similarly, an inhibitor of mutant IDH was shown to reverse blocked differentiation in gliomas and reduced tumor burdens in patient-derived xenografts (Rohle et al., 2013) . Strategic combination of these inhibitors may prove effective in releasing cells trapped in early differentiation stages. In conclusion, our results reveal that these molecular mechanisms outlining how FUBP1 regulates NPC fate can help our understanding of ODG pathogenesis and facilitate the development of novel therapeutic strategies.
EXPERIMENTAL PROCEDURES
Animal experiments
This study was conducted in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals. All procedures were approved by the Institutional Animal Care and Use Committee. were plated on fibronectin-and poly-L-ornithine-coated surface. On day 0, culture medium was replaced with N2 containing BDNF (10 ng/mL, PeproTech), NT-3 (10 ng/mL, PeproTech), B27 (Invitrogen #17504044), and/or doxycycline (2 mg/mL). On day 2, 1% fetal bovine serum was added to the medium to support the fitness of the culture.
NPC Cultures and Induction into Terminally Differentiated Neurons
Mini-Gene Reporter Analysis
A mouse genomic fragment (780 bp) encompassing LSD1 exon 8a was PCR amplified and cloned into pTBNde(min) (Addgene #15125) using the NdeI site. The reporter was further mutagenized on R4, R5, and SRRM4 binding sites by a site-directed mutagenesis kit (Agilent QuikChange Lightning Site-Directed Mutagenesis Kit, #210518). NPC ND1 cells on differentiation day 1 were transfected with 1.2 mg of reporter constructs by Lipofectamine 3000 (Thermo Fisher #L3000008) as previously described (Kim et al., 2015) and harvested for qRT-PCR analysis after 24 hr. Transcript including exon 8a was measured and normalized by the level of total a-globin and fibronectin EDB transcripts. Sequences of oligos used are listed in Supplemental Experimental Procedures.
Statistical Analysis
We determined experimental sample sizes on the basis of preliminary data. All results are expressed as mean ± SEM. GraphPad Prism software (version 7; GraphPad, San Diego, CA) was used for all statistical analysis. Normal distribution of the sample sets was determined before applying unpaired Student's two-tailed t test for two-group comparisons. ANOVA was used to assess the differences between multiple groups. The mean values of each group were compared by the Bonferroni's post hoc procedure. Differences were considered significant when p < 0.05.
ACCESSION NUMBERS
The accession number for the RNA-seq data reported in this paper is GEO: GSE108537. 
SUPPLEMENTAL INFORMATION
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Supplemental Experimental Procedures
RNAseq and data analysis. Total RNAs were isolated from the NPC cultures either under proliferation or after 7 days of differentiation induction, and subjected to RNA sequencing at the Genomics Resources Core facility of Weill Cornell Medicine. RNA-seq libraries were prepared using the Illumina TruSeq stranded mRNA library preparation kit and sequenced on HiSeq4000 sequencer. The Tophat was used to align raw sequencing reads to the UCSC mm9 mouse reference genome, and Cufflinks was used to measure transcript abundances in Reads Per Kilobase of exon model per Million mapped reads (RPKM). RNAseq data is GSE108537 (GSM2902880-2902883)
Mass Spectrometry Analysis. In-gel digestion was performed according to a previous published protocol (Shevchenko et al., 1996) . Briefly, gel pieces were excised and distained, followed by reduction, alkylation and digestion with trypsin (Promega, Madison, WI). The peptides were then extracted from the gels, desalted and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). An EASY-nLC 1200 (Thermo Fisher Scientific) coupled on-line to a Fusion Lumos mass spectrometer (Thermo Fisher Scientific) was used for LC-MS/MS analysis. Buffer A (0.1% formic acid in water) and buffer B (0.1% formic acid and 80% acetonitrile in water) were used as mobile phases for gradient separation. A 75 µm x 15 cm chromatography column (ReproSil-Pur C18-AQ, 3 µm, Dr. Maisch GmbH, German) was packed inhouse for peptide separation. Peptides were separated with a gradient of 5-40% buffer B over 20 min, 40-100% B over 5 min at a flow rate of 300 nL/min. The Fusion Lumos mass spectrometer was operated in data dependent mode with 1 s cycle time. Survey scans were acquired in the Orbitrap mass analyzer over a range of 300-1500 m/z with resolution 120,000 at m/z 200. The most abundant precursors from the survey scan were selected with an isolation window of 1.6 Thomsons and fragmented by higher-energy collisional dissociation with normalized collision energy of 35. MS/MS scans were acquired in the ion trap mass analyzer with rapid scan rate. The automatic gain control target value was 1e6 for MS scans and 1e4 for MS/MS scans respectively, and the maximum ion injection time was 60 ms for both. The raw files were processed using the MaxQuant computational proteomics platform (Cox and Mann, 2008 )(version 1.5.5.1). The fragmentation spectra were searched against the UniProt mouse protein database (contain 80,593 sequences), and allowed up to two missed tryptic cleavages. Oxidation of methionine and protein Nterminal acetylation were used as variable modifications for database searching. Carbamidomethylation of cysteine was used as a fixed modification. The precursor and fragment mass tolerances were set to 7 ppm and 0.5 Da, respectively. Both peptide and protein identifications were filtered at 1% false discovery rate (FDR).
Immunohistochemistry. Formalin-fixed, paraffin-embedded 5 micron sections were used. For stains of brain, sections were processed in standard method and incubated with primary antibodies to mouse anti-NESTIN (1:200, Millipore #MAB353), rabbit anti-PDGFRα (1:200, CST #3174), rabbit anti-OLIG2 (1:500, Millipore #AB9610), rabbit anti-Ki67 (1:300, Vector Laboratories, VP-K451), and rabbit anti-FUBP1 (1:200, Abcam #181111) antibodies and further processed by Vector Elite ABC peroxidase kit followed by developing with DAB substrate and counterstained with hematoxylin.
Immunofluorescence. Cells were fixed with 4% paraformaldehyde for 10 min at room temperature followed by permeabilization with 0.2% triton X-100 in PBS. The cells were subjected to immunofluorescence staining with anti-NESTIN (1:200), anti-OLIG2 (1:500), anti-GFAP (1:500, Origene #TA336707), anti-NeuN (1:200, CST #24307), anti-MAP2a/b (1:200, Abcam #36447), anti-DCX (1:400, Santa Cruz Biotechnology #SC-8066), and anti-β-III tubulin (1:300, Abcam #78078) antibodies overnight at 4°C. The cells were then washed with cold PBS, and incubated with Alexa 488-labeled anti-rabbit and Alexa 568-labeled anti-mouse secondary antibodies (Thermo Fisher Scientific) at room temperature for 1 h. For BrdU immunofluorescence staining, cells were incubated with 0.5 mg/ml of BrdU (Sigma-aldrich #B5002) for 3 h. Then cells were washed 2 times with cold PBS and fixed with 4% paraformaldehyde. Cells were incubated in 1N HCl for 10 min on ice and 2N HCl at 37°C 20 min followed by neutralization with 0.1 M sodium borate buffer pH 8.5 for 10 min at room temperature. Immunofluorescence staining with anti-BrdU (1:500, Dako #M0744) and anti-FUBP1 (1:500, Abcam #181111) antibodies was performed by overnight incubation at 4°C followed by secondary antibody incubation with Alexa 488-labeled anti-rabbit or Alexa 568-labeled anti-mouse secondary antibodies (Thermo Fisher Scientific) at room temperature for 1 h. Images were acquired by fluorescence microscopy with EVOS FL Cell Auto Imaging System. For scoring of marker positive cells for FUBP1 expression levels we used the corrected total cell fluorescence (CTCF = Integrated Density -(area of selected cell X mean fluorescence of background readings)) using ImageJ (Burgess et al., 2010) . Expression level was defined as weak (<5,000), intermediate (5,000~20,000), or strong (>20,000) based on CTCF values.
Western Blot Analysis. Cells were lysed in TNT buffer (0.1 m Tris-HCl, pH 7.5. 0.15 m NaCl. 0.05% (v/v) Tween 20) supplemented with a protease and phosphatase inhibitor cocktail. Ten µg of cell lysates were fractionated by SDS-PAGE and transferred to a PVDF membrane. After incubation with 5% non-fat dried milk in TBST (10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) for 1 h, the membrane was washed once with TBST and incubated with antibodies against β-actin (1:5,000, Sigma-Aldrich #A3853), FUBP1 (1:2,000), OLIG2 (1:2,000), MAP2 (CST #8707), GFAP (1:5,000), β-III tubulin (1:1,000), and LSD1 (1:1,000, Abcam #17721) at 4 °C for 16 h. Membranes were washed three times for 10 min and incubated with a 1:10,000 dilution of horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies for 1 h. Blots were washed with TBST three times and developed with the SuperSignal™ West Femto substrate (Thermo Fisher Scientific).
Alternative splicing analysis. We used rMATS v3.0.9 (http://rnaseq-mats.sourceforge.net) (Shen et al., 2014) to identify differential alternative splicing events from single end RNA-seq data corresponding to all five basic types of alternative splicing patterns ( Figure S6 ). For each alternative splicing event, we used the reads alignment against genome as the input for rMATS and set the cutoff splicing difference to be 0.05.
Intracranial orthotopic grafting and bioluminescence imaging. This study was conducted in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals. All procedures on mice were approved by the Institutional Animal Care and Use Committee. Above described Ink/Arf -/-NPCs with TRC or shFUBP1-1 were further transduced with viral particles made by packaging pBabe-IDH1 R132H or pLP-LNCX-PIK3CA H1047R (a gift from Todd Waldman, Addgene # 25635), along with mCherryluciferase expressing vector. Ten thousand of these NPCs were injected into front-lobe caudate nucleus of 4-6 week-old immunodeficient NOD/scid-IL2Rgc knockout (NSG) mice (JAX) for Figure 6E -F or NCG (#572, Charles River) for Figure 6G -H using a stereotaxic injector as previously described (Klingler et al., 2015) . Mice were subjected to weekly bioluminescent imaging for tumor development. Briefly, mice were given intraperitoneal injections of D-Luciferin (150 mg/kg, Goldbio) and imaged 5 min after the injection using the IVIS® Spectrum in vivo imaging system following the manufacturer's instructions. Mice were monitored daily, and sacrificed at onset of neurological symptoms. At the time of sacrifice, tumor tissues were collected for histological evaluations. qRT-PCR analysis. RNA was harvested using NucleoSpin® RNA (MACHEREY-NAGEL). Then, one microgram of total RNA was reverse transcribed into cDNA utilizing RevertAit RT kit (Thermo #K1691). Quantitative RT-PCR was performed on cDNA samples using the Power SYBR® Green Master mix (Applied Biosystems) and was performed the qPCR on Applied Biosystem 7500 Fast Real-Time PCR system. Primer sequences are as below. Each samples were run as duplicates (triplicates) and the mRNA level of each samples was normalized to that of the β-actin mRNA. 
RNA-immunoprecipitation. NPC
ND1 cells were differentiated for 2.5 days in the presence of 1 µg/ml of doxycycline. 8x10 6 cells were cross-linked for 5 min with 1% paraformaldehyde (Thermo #28906) and quenched with 120 mM glycine for 5 min. After nucleus isolation, the total RNA was sheared using the Covaris M220 Focused-ultrasonicator according to the manufacturer's instructions. Immunoprecipitation was performed with 4 µg of anti-FUBP1 antibody (Abcam #181111), 4 µg of anti-Flag antibody (GeneScript #A00187), or 4 µg of normal IgG antibody. After purification of RNA with Trizol® (Thermo #15596026), the samples were treated with RNase-free DNaseI (Sigma-aldrich #AMPD1-1KT) for 30 min to remove genomic DNA. cDNA was synthesized with RevertAit RT kit (Thermo #K1691). Quantitative RT-PCR was performed on cDNA samples using the Power SYBR® Green Master mix (Applied Biosystems) and was performed the qPCR on Applied Biosystem 7500 Fast Real-Time PCR system. 
Primers for RNA-IP analysis
